| Source: |
| Type: protein |
| Also known as SLC2A1 An important hallmark in cancer cells is the increase in glucose uptake. GLUT1 is an important target in cancer treatment because cancer cells upregulate GLUT1, a membrane protein that facilitates the basal uptake of glucose in most cell types, to ensure the flux of sugar into metabolic pathways. GLUT1 is a member of the facilitated glucose transporter family and is widely expressed in various tissues, including red blood cells, brain, and cancer cells. GLUT1 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glucose uptake and energy production in cancer cells. GLUT1 is a protein that facilitates the transport of glucose across cell membranes. GLUT1 plays a role in the regulation of glucose metabolism in diabetes. GLUT1 plays a role in the regulation of glucose metabolism in diabetes. GLUT1 is also known to be involved in the Warburg effect. GLUTs are expressed 10–12-fold higher in cancer cells than in healthy tissues, especially in highly proliferative and malignant tumors. Downregulators: -Resveratrol: associated with reduced GLUT1 expression. -Curcumin: downregulate GLUT1 in various cancer cell lines -Quercetin: downregulating the expression and function of GLUT1. -EGCG: suppress GLUT1 expression -Berberine: linked to decreased expression or activity of GLUT1. |
| Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4) |
| 206- | Api, | Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Lung, | H2030 | - | in-vitro, | CRC, | SW480 |
| 566- | ART/DHA, | 2DG, | Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
| 2619- | Ba, | Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MGC803 | - | in-vitro, | Lung, | A549 |
| 2618- | Ba, | Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 1259- | CAP, | Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H2009 |
| 3064- | RES, | Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | BC, | T47D | - | in-vitro, | Lung, | LLC1 |
| 2182- | SK, | Cisplatin, | Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 | - | in-vivo, | NA, | NA |
| 2365- | VitD3, | Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1975 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:15 Cells:% prod#:% Target#:566 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid